Diabetes and mood disorders: shared mechanisms and therapeutic opportunities

References

• Abdallah MS, Mosalam EM, Zidan A-AA, Elattar KS, Zaki SA, Ramadan AN, Ebeid AM. 2020. The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: a proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics. 17(4):1897–1906.
   PubMed Web of Science ®Google Scholar
• Abrahamian H, Kautzky-Willer A, Rießland-Seifert A, Fasching P, Ebenbichler C, Kautzky A, Hofmann P, Toplak H. 2019. [Mental disorders and diabetes mellitus (Update 2019)]. Wien Klin Wochenschr. 131(Suppl 1):186–195.
   PubMedGoogle Scholar
• Aftab A, Kemp DE, Ganocy SJ, Schinagle M, Conroy C, Brownrigg B, D'Arcangelo N, Goto T, Woods N, Serrano MB, et al. 2019. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 245:957–964.
   PubMed Web of Science ®Google Scholar
• AlHussain F, AlRuthia Y, Al-Mandeel H, Bellahwal A, Alharbi F, Almogbel Y, Awwad O, Dala'een R, Alharbi FA. 2020. Metformin improves the depression symptoms of women with polycystic ovary syndrome in a lifestyle modification program. Patient Prefer Adherence. 14:737–746.
   PubMed Web of Science ®Google Scholar
• Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE. 2018. Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. Front Neurosci. 12:386.
   PubMed Web of Science ®Google Scholar
• Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang H-Y, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, et al. 2018. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 14(3):168–181.
   PubMed Web of Science ®Google Scholar
• Bansal Y, Kuhad A. 2016. Mitochondrial dysfunction in depression. Curr Neuropharmacol. 14(6):610–618.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, et al. 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 93(1–3):99–108.
   PubMed Web of Science ®Google Scholar
• Barnard K, Peveler RC, Holt RIG. 2013. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care. 36(10):3337–3345.
   PubMed Web of Science ®Google Scholar
• Batista AF, Forny-Germano L, Clarke JR, Lyra E Silva NM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC, Lablans A, Vital JF, et al. 2018. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. J Pathol. 245(1):85–100.
   PubMed Web of Science ®Google Scholar
• Benedict C. 2004. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 29(10):1326–1334.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U. 2013. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 29(4):273–284.
   PubMed Web of Science ®Google Scholar
• Brown LC, Majumdar SR, Johnson JA. 2008. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract. 79(1):61–67.
   PubMed Web of Science ®Google Scholar
• Buchberger B, Huppertz H, Krabbe L, Lux B, Mattivi JT, Siafarikas A. 2016. Symptoms of depression and anxiety in youth with type 1 diabetes: a systematic review and meta-analysis. Psychoneuroendocrinology. 70:70–84.
   PubMed Web of Science ®Google Scholar
• Cade WT. 2008. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 88(11):1322–1335.
   PubMed Web of Science ®Google Scholar
• Cai W, Xue C, Sakaguchi M, Konishi M, Shirazian A, Ferris HA, Li ME, Yu R, Kleinridders A, Pothos EN, et al. 2018. Insulin regulates astrocyte gliotransmission and modulates behavior. J Clin Invest. 128(7):2914–2926.
   PubMed Web of Science ®Google Scholar
• Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, O'Donovan MC, Alda M. 2015. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 206(1):52–57.
   PubMed Web of Science ®Google Scholar
• Cha DS, Best MW, Bowie CR, Gallaugher LA, Woldeyohannes HO, Soczynska JK, Lewis G, MacQueen G, Sahakian BJ, Kennedy SH, et al. 2017. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. J Affect Disord. 210:57–65.
   PubMed Web of Science ®Google Scholar
• Ciechanowski PS, Katon WJ, Russo JE. 2000. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 160(21):3278–3285.
   PubMed Web of Science ®Google Scholar
• Coelho PV, Brum CA. 2009. Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Coronel Fabriciano, Minas Gerais State, Brazil. Cad Saude Publica. 25(10):2229–2236.
   PubMed Web of Science ®Google Scholar
• Coello K, Vinberg M, Knop FK, Pedersen BK, McIntyre RS, Kessing LV, Munkholm K. 2019. Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Int J Bipolar Disord. 7(1):8.
   PubMedGoogle Scholar
• Colpo GD, Leboyer M, Dantzer R, Trivedi MH, Teixeira AL. 2018. Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother. 18(2):139–152.
   PubMed Web of Science ®Google Scholar
• de la Monte SM. 2012. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 9(1):35–66.
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. 2010. A meta-analysis of cytokines in major depression. Biol Psychiatry. 67(5):446–457.
   PubMed Web of Science ®Google Scholar
• Echeverry D, Duran P, Bonds C, Lee M, Davidson MB. 2009. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 32(12):2156–2160.
   PubMed Web of Science ®Google Scholar
• Farooqi A, Khunti K, Abner S, Gillies C, Morriss R, Seidu S. 2019. Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 156:107816.
   PubMed Web of Science ®Google Scholar
• Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, Allan S, Caneo C, Carney R, Carvalho AF, et al. 2019. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 6(8):675–712.
   PubMed Web of Science ®Google Scholar
• Ford AH, Flicker L, Hankey GJ, Yeap BB, Chubb SAP, Golledge J, Almeida OP. 2015. Insulin resistance and depressive symptoms in older men: the health in men study. Am J Geriatr Psychiatry. 23(8):872–880.
   PubMed Web of Science ®Google Scholar
• Fries GR, Walss-Bass C, Bauer ME, Teixeira AL. 2019. Revisiting inflammation in bipolar disorder. Pharmacol Biochem Behav. 177:12–19.
   PubMed Web of Science ®Google Scholar
• Gagnon J, Lussier MT, MacGibbon B, Daskalopoulou SS, Bartlett G. 2018. The impact of antidepressant therapy on glycemic control in Canadian primary care patients with diabetes mellitus. Front Nutr. 5:47.
   PubMed Web of Science ®Google Scholar
• Geer EB, Islam J, Buettner C. 2014. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 43(1):75–102.
   PubMed Web of Science ®Google Scholar
• Ghaeli P, Shahsavand E, Mesbahi M, Kamkar M-Z, Sadeghi M, Dashti-Khavidaki S. 2004. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol. 24(4):386–388.
   PubMed Web of Science ®Google Scholar
• Goncalves P, Araújo JR, Martel F. 2015. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol. 25(1):1–16.
   PubMed Web of Science ®Google Scholar
• Gonzalez JS, Safren SA, Cagliero E, Wexler DJ, Delahanty L, Wittenberg E, Blais MA, Meigs JB, Grant RW. 2007. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care. 30(9):2222–2227.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Muniesa P, Mártinez-González MA, Hu FB, Després JP, Matsuzawa Y, Loos RJF, Moreno LA, Bray GA, Martinez JA. 2017. Obesity. Nat Rev Dis Primers. 3(1):1–18.
   Google Scholar
• Gray SM, Aylor KW, Barrett EJ. 2017. Unravelling the regulation of insulin transport across the brain endothelial cell. Diabetologia. 60(8):1512–1521.
   PubMed Web of Science ®Google Scholar
• Grillo CA, Piroli GG, Kaigler KF, Wilson SP, Wilson MA, Reagan LP. 2011. Downregulation of hypothalamic insulin receptor expression elicits depressive-like behaviors in rats. Behav Brain Res. 222(1):230–235.
   PubMed Web of Science ®Google Scholar
• Guha P, Bhowmick K, Mazumder P, Ghosal M, Chakraborty I, Burman P. 2014. Assessment of insulin resistance and metabolic syndrome in drug naive patients of bipolar disorder. Ind J Clin Biochem. 29(1):51–56.
   PubMedGoogle Scholar
• Guo M, Mi J, Jiang Q-M, Xu J-M, Tang Y-Y, Tian G, Wang B. 2014. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 41(9):650–656.
   PubMed Web of Science ®Google Scholar
• Guo S. 2014. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 220(2):T1–T23.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. 2005. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 128(Pt 6):1442–1453.
   PubMedGoogle Scholar
• Heni M, Schöpfer P, Peter A, Sartorius T, Fritsche A, Synofzik M, Häring H-U, Maetzler W, Hennige AM. 2014. Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. Acta Diabetol. 51(4):679–681.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. 2014. Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord. 169:S12–S16.
   PubMed Web of Science ®Google Scholar
• Ho N, Sommers MS, Lucki I. 2013. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev. 37(8):1346–1362.
   PubMed Web of Science ®Google Scholar
• Holt RIG, de Groot M, Golden SH. 2014. Diabetes and depression. Curr Diab Rep. 14(6):491.
   PubMed Web of Science ®Google Scholar
• Howren MB, Lamkin DM, Suls J. 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 71(2):171–186.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wei X, Wu T, Chen R, Guo A. 2013. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry. 13:260.
   PubMed Web of Science ®Google Scholar
• Hutter N, Scheidt-Nave C, Baumeister H. 2009. Health care utilisation and quality of life in individuals with diabetes and comorbid mental disorders. Gen Hosp Psychiatry. 31(1):33–35.
   PubMed Web of Science ®Google Scholar
• Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML, et al. 2017. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 15(1):23.
   PubMed Web of Science ®Google Scholar
• Jia Y, Liu L, Sheng C, Cheng Z, Cui L, Li M, Zhao Y, Shi T, Yau TO, Li F, et al. 2019. Increased serum levels of cortisol and inflammatory cytokines in people with depression. J Nerv Ment Dis. 207(4):271–276.
   PubMed Web of Science ®Google Scholar
• Jorm AF, Patten SB, Brugha TS, Mojtabai R. 2017. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry. 16(1):90–99.
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Golden SH. 2017. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci. 1391(1):20–34.
   PubMed Web of Science ®Google Scholar
• Kamarck TW, Muldoon MF, Manuck SB, Haskett RF, Cheong JWon, Flory JD, Vella E. 2011. Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention. Psychoneuroendocrinology. 36(7):1070–1079.
   PubMed Web of Science ®Google Scholar
• Kammer JR, Hosler AS, Leckman-Westin E, DiRienzo G, Osborn CY. 2016. The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS). J Diabetes Complications. 30(2):242–247.
   PubMed Web of Science ®Google Scholar
• Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, Ismail K. 2013. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 36(2):480–489.
   PubMed Web of Science ®Google Scholar
• Kang D, Jing Z, Li R, Hei G, Shao T, Li L, Sun M, Yang Y, Wang Y, Wang X, et al. 2018. Effect of betahistine and metformin on antipsychotic-induced weight gain: an analysis of two clinical trials. Front Psychiatry. 9:620.
   PubMed Web of Science ®Google Scholar
• Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S. 2013. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 38(6):767–776.
   PubMed Web of Science ®Google Scholar
• Katon WJ, Rutter C, Simon G, Lin EHB, Ludman E, Ciechanowski P, Kinder L, Young B, Von Korff M. 2005. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 28(11):2668–2672.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR. 2012. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 136(3):1164–1173.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR. 2014. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 28(6):571–581.
   PubMed Web of Science ®Google Scholar
• Khan A, Mar KF, Schilling J, Brown WA. 2018. Magnitude and pattern of placebo response in clinical trials of oral antihyperglycemic agents: data from the U.S. Food and Drug Administration, 1999–2015. Diabetes Care. 41(5):994–1000.
   PubMed Web of Science ®Google Scholar
• Kivimaki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, Brunner EJ, Tabak AG, Witte DR, Kumari M, et al. 2011. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry. 70(10):978–984.
   PubMed Web of Science ®Google Scholar
• Kivimaki M, Batty GD. 2015. Commentary: antidepressants and diabetes risk: why are there discrepant findings from cohort studies based on patient records and those based on serial phenotyping? Int J Epidemiol. 44(6):1940–1942.
   PubMed Web of Science ®Google Scholar
• Komorousova J, Beran J, Rusavy Z, Jankovec Z. 2010. Glycemic control improvement through treatment of depression using antidepressant drugs in patients with diabetes mellitus type 1. Neuro Endocrinol Lett. 31(6):801–806.
   PubMed Web of Science ®Google Scholar
• Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B. 2010. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 62(5):956–965.
   PubMed Web of Science ®Google Scholar
• Lin KW, Wroolie TE, Robakis T, Rasgon NL. 2015. Adjuvant pioglitazone for unremitted depression: clinical correlates of treatment response. Psychiatry Res. 230(3):846–852.
   PubMed Web of Science ®Google Scholar
• Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH, Zitman FG. 2010. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 67(3):220–229.
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. 2000. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 23(7):934–942.
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Freedland KE, Griffith LS, Clouse RE. 2000. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 23(5):618–623.
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB. 2006. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 63(5):521–529.
   PubMed Web of Science ®Google Scholar
• Lyra E Silva NM, Lam MP, Soares CN, Munoz DP, Milev R, De Felice FG. 2019. Insulin resistance as a shared pathogenic mechanism between depression and type 2 diabetes. Front Psychiatry. 10:57.
   PubMed Web of Science ®Google Scholar
• Mark TL. 2010. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians. CNS Drugs. 24(4):319–326.
   PubMed Web of Science ®Google Scholar
• Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. 2011. A review of treating depression in diabetes: emerging findings. Psychosomatics. 52(1):1–18.
   PubMed Web of Science ®Google Scholar
• Marvel CL, Paradiso S. 2004. Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am. 27(1):19–36.
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, Hölscher C. 2011. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 31(17):6587–6594.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, Lewis GF, Kennedy SH. 2012. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 14(7):697–706.
   PubMed Web of Science ®Google Scholar
• Moulton CD, Hopkins CWP, Ismail K, Stahl D. 2018. Repositioning of diabetes treatments for depressive symptoms: a systematic review and meta-analysis of clinical trials. Psychoneuroendocrinology. 94:91–103.
   PubMed Web of Science ®Google Scholar
• Nandam LS, Brazel M, Zhou M, Jhaveri DJ. 2019. Cortisol and major depressive disorder-translating findings from humans to animal models and back. Front Psychiatry. 10:974.
   PubMed Web of Science ®Google Scholar
• Opie RS, O'Neil A, Itsiopoulos C, Jacka FN. 2015. The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials. Public Health Nutr. 18(11):2074–2093.
   PubMed Web of Science ®Google Scholar
• Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. 2003. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 4:7.
   PubMedGoogle Scholar
• Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. 2007. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract. 8:34.
   PubMed Web of Science ®Google Scholar
• Park M, Katon WJ, Wolf FM. 2013. Depression and risk of mortality in individuals with diabetes: a meta-analysis and systematic review. Gen Hosp Psychiatry. 35(3):217–225.
   PubMed Web of Science ®Google Scholar
• Parker GF. 2014. DSM-5 and psychotic and mood disorders. J Am Acad Psychiatry Law. 42(2):182–190.
   PubMedGoogle Scholar
• Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. 2015. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 47(1):4–11.
   PubMedGoogle Scholar
• Pecina M, Bohnert ASB, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta JK. 2015. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psychiatry. 72(11):1087–1094.
   PubMed Web of Science ®Google Scholar
• Platzer M, Fellendorf FT, Bengesser SA, Birner A, Dalkner N, Hamm C, Lenger M, Maget A, Pilz R, Queissner R, et al. 2020. The relationship between food craving, appetite-related hormones and clinical parameters in bipolar disorder. Nutrients. 13(1):1–76.
   Web of Science ®Google Scholar
• Rakofsky J, Rapaport M. 2018. Mood disorders. Continuum. 24(3):804–827.
   PubMedGoogle Scholar
• Reus GZ, Carlessi AS, Silva RH, Ceretta LB, Quevedo J. 2019. Relationship of oxidative stress as a link between diabetes mellitus and major depressive disorder. Oxid Med Cell Longev. 2019:1–6.
   Web of Science ®Google Scholar
• Rizvi SMD, Shaikh S, Waseem SMA, Shakil S, Abuzenadah AM, Biswas D, Tabrez S, Ashraf GM, Kamal MA. 2015. Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. Excli J. 14:684–696.
   PubMed Web of Science ®Google Scholar
• Ruzickova M, Slaney C, Garnham J, Alda M. 2003. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 48(7):458–461.
   PubMed Web of Science ®Google Scholar
• Salvi V, Grua I, Cerveri G, Mencacci C, Barone-Adesi F. 2017. The risk of new-onset diabetes in antidepressant users - a systematic review and meta-analysis. PLoS One. 12(7):e0182088.
   PubMed Web of Science ®Google Scholar
• Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. 2016. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 77:42–51.
   PubMed Web of Science ®Google Scholar
• Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia M-J, Akhondzadeh S. 2012. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacol. 37(9):2093–2100.
   PubMed Web of Science ®Google Scholar
• Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. 2020. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med. 18(1):261.
   PubMed Web of Science ®Google Scholar
• Stalder T, Steudte-Schmiedgen S, Alexander N, Klucken T, Vater A, Wichmann S, Kirschbaum C, Miller R. 2017. Stress-related and basic determinants of hair cortisol in humans: a meta-analysis. Psychoneuroendocrinology. 77:261–274.
   PubMed Web of Science ®Google Scholar
• Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. 2003. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 285(2):E433–E437.
   PubMed Web of Science ®Google Scholar
• Stetler C, Miller GE. 2011. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 73(2):114–126.
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. 2015. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 25(10):1532–1543.
   PubMed Web of Science ®Google Scholar
• Tully A, Smyth S, Conway Y, Geddes J, Devane D, Kelly JP, Jordan F. 2020. Interventions for the management of obesity in people with bipolar disorder. Cochrane Database Syst Rev. 7:CD013006.
   PubMedGoogle Scholar
• van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W, Snoek F, Sartorius N. 2010. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 32(4):380–395.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang S, Zong Q-Q, Zhang Q, Ng CH, Ungvari GS, Xiang Y-T. 2019. Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies. Diabet Med. 36(8):961–969.
   PubMed Web of Science ®Google Scholar
• Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I, Deuschle M. 2007. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res. 41(3–4):344–350.
   PubMed Web of Science ®Google Scholar
• Xu J, Mercury J, Zhang Z, Xu F. 2008. Psychological, social and behavioural factors that influence drug efficacy: a noteworthy research subject in clinical pharmacology. Br J Clin Pharmacol. 66(6):901–902.
   PubMed Web of Science ®Google Scholar
• Xue H. 2004. Paroxetine for depression in diabetes: a randomized controlled trial. Chin Ment Health J. 18:735–737.
   Google Scholar
• Ye Z, Chen L, Yang Z, Li Q, Huang Y, He M, Zhang S, Zhang Z, Wang X, Zhao W, et al. 2011. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One. 6(7):e21551.
   PubMed Web of Science ®Google Scholar
• Yoon JM, Cho E-G, Lee H-K, Park SM. 2013. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med. 34(4):228–240.
   PubMedGoogle Scholar
• Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. 2016. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care. 39(12):2126–2140.
   PubMed Web of Science ®Google Scholar
• Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S. 2015. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 32(3):167–173.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Okusaga OO, Quevedo J, Soares JC, Teixeira AL. 2016. The potential association between obesity and bipolar disorder: a meta-analysis. J Affect Disord. 202:120–123.
   PubMed Web of Science ®Google Scholar